The difference between dacomitinib and gefitinib

Dacomitinib (Dacomitinib) and gefitinib (Gefitinib) are two targeted treatments for non-small cell lung cancer (NSCLC). Dacomitinib and gefitinib are both tyrosine kinase inhibitors (TKIs), but their mechanisms of action are slightly different. Dacomitinib inhibits the activity of multiple epidermal growth factor receptor (EGFR) family members, including EGFR, HER2, and HER4. Gefitinib mainly inhibits the activity of EGFR. In clinical trials, dacomitinib has been shown to be more effective than gefitinib in extending progression-free survival. A study called ARCHER 1050 showed that dacomitinib prolonged progression-free survival compared with gefitinib in first-line treatment.